<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JCP</journal-id>
<journal-id journal-id-type="hwp">jclinpharm</journal-id>
<journal-id journal-id-type="nlm-ta">J Clin Pharmacol</journal-id>
<journal-title>The Journal of Clinical Pharmacology</journal-title>
<issn pub-type="ppub">0091-2700</issn>
<issn pub-type="epub">1552-4604</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0091270010396373</article-id>
<article-id pub-id-type="publisher-id">10.1177_0091270010396373</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacokinetics</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Population Pharmacokinetic Model for a Novel Oral Hypoglycemic Formed In Vivo</article-title>
<subtitle>Comparing the Use of Active Metabolite Data Alone Versus Using Data of Upstream and Downstream Metabolites</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Kastrissios</surname><given-names>Helen</given-names></name>
<degrees>PhD</degrees>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Walker</surname><given-names>Joseph R.</given-names></name>
<degrees>PharmD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Carrothers</surname><given-names>Timothy J.</given-names></name>
<degrees>ScD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Kshirsagar</surname><given-names>Smita</given-names></name>
<degrees>PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Khariton</surname><given-names>Tatiana</given-names></name>
<degrees>PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Habtemariam</surname><given-names>Bahru</given-names></name>
<degrees>PharmD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Mager</surname><given-names>Donald E.</given-names></name>
<degrees>PharmD, PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Rohatagi</surname><given-names>Shashank</given-names></name>
<degrees>PhD, MBA</degrees>
</contrib>
</contrib-group>
<aff id="aff1-0091270010396373">Pharsight Corporation, Mountain View, California (Dr Kastrissios, Dr Carrothers, Dr Kshirsagar, Dr Khariton)</aff>
<aff id="aff2-0091270010396373">Daiichi Sankyo Pharma Development, Edison, New Jersey (Dr Walker and Dr Rohatagi)</aff>
<aff id="aff3-0091270010396373">Department of Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, New York (Dr Habtemariam and Dr Mager)</aff>
<author-notes>
<corresp id="corresp1-0091270010396373">Joseph R. Walker, PharmD, Daiichi Sankyo Pharma Development, 399 Thornall Street, Edison, NJ 08837 USA; e-mail: <email>jwalker@dsi.com</email>.</corresp>
<fn fn-type="other">
<p>Dr Mager and Dr Rohatagi are fellows of the American College of Clinical Pharmacology.</p>
</fn>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2012</year>
</pub-date>
<volume>52</volume>
<issue>3</issue>
<fpage>404</fpage>
<lpage>415</lpage>
<history>
<date date-type="received">
<day>16</day>
<month>4</month>
<year>2010</year>
</date>
<date date-type="accepted">
<day>28</day>
<month>11</month>
<year>2010</year>
</date>
</history>
<permissions>
<copyright-statement>© 2012 American College of Clinical Pharmacology, Inc.</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">American College of Clinical Pharmacology, Inc.</copyright-holder>
</permissions>
<abstract>
<p>The purpose of this analysis was to develop a population pharmacokinetic model for CS-917, an oral hypoglycemic prodrug, and its 3 metabolites. The population pharmacokinetic model was used to predict exposure of the active moiety R-125338 and thus to identify potential CS-917 dosage reduction criteria. The dataset included 6 phase I and IIa studies in patients with type 2 diabetes mellitus. The pharmacokinetic profile of CS-917 and its metabolites was described by a series of linked 1- and 2-compartmental models. Simulations showed that moderate renal impairment has a clinically significant impact on exposure to R-125338. A separate population pharmacokinetic analysis of R-125338 alone revealed similar results. In conclusion, a population pharmacokinetic model fit to the active moiety alone yielded similar predictions and substantially reduced the analysis time compared to the more complex model developed for CS-917 and its metabolites. Increased exposure to R-125338 in the presence of moderate renal impairment may be an important consideration for dose selection.</p>
</abstract>
<kwd-group>
<kwd>CS-917</kwd>
<kwd>population pharmacokinetics</kwd>
<kwd>type 2 diabetes mellitus</kwd>
<kwd>fructose-1</kwd>
<kwd>6-bisphosphatase</kwd>
<kwd>managlinat dialanetil</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>CS-917 (International Nonproprietary Name: managlinat dialanetil) is intended to be an orally administered prodrug intended to control and reduce hyperglycemia in type 2 diabetes. The active metabolite R-125338 is a potent and specific nonnucleotide inhibitor of human liver fructose-1,6-bisphosphatase, an enzyme that catalyzes the rate-limiting step (ie, conversion of fructose-1,6-bisphosphate to fructose 6-phosphate) in the gluconeogenesis pathway. Inhibition of hepatic gluconeogenesis is an attractive therapeutic goal in type 2 diabetes. Elevated rates of endogenous glucose production are characteristic of the disorder. Elevated gluconeogenesis is correlated with not only fasting hyperglycemia but also postprandial hyperglycemia.<sup><xref ref-type="bibr" rid="bibr1-0091270010396373">1</xref>,<xref ref-type="bibr" rid="bibr2-0091270010396373">2</xref></sup> Metformin, one of the most successful and widely employed oral antidiabetic agents, lowers blood glucose concentrations, at least in part, through inhibition of hepatic gluconeogenesis.<sup><xref ref-type="bibr" rid="bibr3-0091270010396373">3</xref></sup> Hence, fructose 1,6-bisphosphatase is an attractive therapeutic target for managing type 2 diabetes, and based on preclinical in vitro and in vivo studies, CS-917 is a more specific and potent gluconeogenesis inhibitor than metformin.<sup><xref ref-type="bibr" rid="bibr4-0091270010396373">4</xref></sup></p>
<p>In humans, CS-917 is well tolerated, rapidly absorbed, extensively metabolized, and rapidly cleared from plasma.<sup><xref ref-type="bibr" rid="bibr5-0091270010396373">5</xref></sup> Although in vitro studies have shown that CS-917 is a substrate of CYP3A4, the contribution of CYPs to the overall metabolism of CS-917 and its metabolites is low. CS-917 is rapidly converted by an esterase to an inactive metabolite, R-134450, which in turn undergoes intracellular hydrolysis in the liver by phosphoramidase to R-125338, the active metabolite. R-125338 undergoes considerable renal excretion as well as N-acetylation to an inactive metabolite, R-143047, which forms slowly and exhibits a long half-life.<sup><xref ref-type="bibr" rid="bibr5-0091270010396373">5</xref></sup></p>
<p>In humans, safety and tolerability have been generally favorable at total daily doses of 400 mg.<sup><xref ref-type="bibr" rid="bibr6-0091270010396373">6</xref></sup> CS-917 treatment for 28 days has been shown to effectively lower fasting and postprandial glucose in patients with type 2 diabetes mellitus (data on file: CS0917-A-2B).</p>
<p>The purpose of this analysis was to develop a population pharmacokinetic model describing the formation of the active moiety R-125338 from the prodrug CS-917 and to identify covariates influencing R-125338 exposure. Two approaches were compared. The first approach involved the development of a series of linked compartmental models incorporating data for the prodrug as well as upstream and downstream metabolites relative to R-125338 (Figure 1). A second analytical approach included data for R-125338 only.</p>
<sec id="section1-0091270010396373" sec-type="methods">
<title>Methods</title>
<sec id="section2-0091270010396373">
<title>Data</title>
<p>Data from 4 phase I studies (A, B, E, and F) and 2 phase IIa studies (C and D) were included in the pharmacokinetic analysis. Each study was approved by the institutional review board at each institution, and each patient gave written informed consent for participation. <xref ref-type="table" rid="table1-0091270010396373">Table I</xref> presents a summary of the studies.</p>
<table-wrap id="table1-0091270010396373" position="float">
<label>Table I</label>
<caption><p>Clinical Studies Used in the Analysis</p></caption>
<graphic alternate-form-of="table1-0091270010396373" xlink:href="10.1177_0091270010396373-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="center"/>
<col align="center"/>
<col align="left"/>
<col align="center"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Study</th>
<th align="center">Design</th>
<th align="center">Phase of Development</th>
<th align="center">n</th>
<th align="center">Treatments</th>
<th align="center">Duration, Days</th>
<th align="center">Administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Parallel</td>
<td>I</td>
<td>16</td>
<td>A: CS-917 400 mg BID (tablet)<break/>B: placebo<break/>C: metformin</td>
<td>21</td>
<td>With breakfast (± 30 min) and with evening snack (± 30 min)</td>
</tr>
<tr>
<td>B</td>
<td>Three-way crossover</td>
<td>I</td>
<td>21</td>
<td>A: day 1 to day 5: 100 mg CS-917 BID; day 6 to day 10: 200 mg CS-917 BID; day 14 morning: 200 mg CS-917 SD<break/>B: glibenclamide<break/>C: CS-917 + glibenclamide</td>
<td>14/period</td>
<td>With breakfast (5 min before)</td>
<td/>
</tr>
<tr>
<td>C</td>
<td>Parallel, ascending combination</td>
<td>IIa</td>
<td>53</td>
<td>CS-917 50 mg QD (capsule)<break/>CS-917 100 mg QD<break/>CS-917 200 mg QD<break/>CS-917 400 mg (<sc>am</sc> and <sc>pm</sc> dosing)<break/>Placebo</td>
<td>14</td>
<td>Days −1, 1, 14: fast 12 hours before dosing and 6 hours after<break/>Days 2-13: fast 8 hours before dosing and 2 hours after<break/>400-mg evening dosing group not required to fast</td>
</tr>
<tr>
<td>D</td>
<td>Parallel</td>
<td>IIa</td>
<td>148</td>
<td>CS-917 100 mg BID (tablet)<break/>CS-917 200 mg BID (tablet)<break/>CS-917 100 mg TID (tablet)<break/>Placebo</td>
<td>28</td>
<td>With breakfast (± 30 min), midday meal (± 30 min), evening snack (± 30 min)</td>
</tr>
<tr>
<td>E</td>
<td>Three-way crossover</td>
<td>I</td>
<td>24</td>
<td>A: 200 mg CS-917 BID (tablet)<break/>B: pioglitazone<break/>C: CS-917 + pioglitazone</td>
<td>10/period</td>
<td>With breakfast (± 5 min) and with the dinner (± 30 min)</td>
</tr>
<tr>
<td>F</td>
<td>Parallel, ascending combination</td>
<td>I</td>
<td>32</td>
<td>100 mg CS-917 BID (tablet)<break/>200 mg CS-917 BID (tablet)<break/>Metformin</td>
<td>28</td>
<td>With breakfast (± 30 min) and with the evening snack (± 30 min)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0091270010396373">
<p>Population for each study: patients with noninsulin-dependent diabetes mellitus. BID, twice daily; QD, every day; SD, single dose; TID, 3 times daily.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Bioanalysis of CS-917, R-134450, R-125338, and R-143047 in human plasma anticoagulated with sodium citrate was conducted by MDS Pharma Services (St-Laurent, Quebec, Canada) using a validated high-performance liquid chromatography with tandem mass spectrometric detection method. All 4 analytes were quantified in each run using deuterated forms of the analytes as internal standards. Plasma assays were linear and reproducible in the range 5 to 2000 ng/mL for CS-917, R-134450, and R-125338 and 10 to 2000 ng/mL for R-143047. Intrabatch and interbatch accuracy and precision for daily standards and seeded quality controls were &lt; 11.5% and &lt; 12%, respectively, for all analytes across the analytical range of plasma concentrations.</p>
<p>The pharmacokinetic data set included 8961 observations from 141 patients (90 men, 51 women) with type 2 diabetes mellitus. Diabetic patients were included in these studies if hemoglobin A1c was ≥ 6.5% and fasting plasma glucose was 160 to 300 mg/dL at baseline. All subjects in the pharmacokinetic data set received multiple oral doses of CS-917. With the exception of study C, all patients received 2 doses of CS-917 per day, with food. Those in study C were fasted before dosing and for up to 6 hours after receiving 1 daily dose in the mornings.</p>
<p>When pharmacokinetic sampling was performed, study drug was administered to the patients on-site. The times of both the dose taken in the clinic and the previous dose were recorded. Only observations collected during monotherapy treatment with CS-917 were included in the development of the structural model. Pharmacokinetic samples that were collected during combination therapy or recorded as zero, below the limit of detection or missing, were excluded from the analysis.</p>
<p>Covariates included patient demographics, food status at time of dosing, and laboratory markers of renal and hepatic function. Demographic variables were collected at the screening visit and included age (years), body weight (kg), body mass index (kg/m<sup>2</sup>), sex, and race (white, black, and Hispanic). Food status was evaluated as fasted capsule versus tablet with food; food status but not formulation was evaluated since capsule and tablet were shown to be bioequivalent (data on file: CTR-917-101). Laboratory markers of hepatic function recorded at baseline included serum alanine aminotransferase, serum aspartate aminotransferase, and total bilirubin. Creatinine clearance (CLCR) was computed using the Cockcroft-Gault equation.<sup><xref ref-type="bibr" rid="bibr7-0091270010396373">7</xref></sup></p>
</sec>
<sec id="section3-0091270010396373">
<title>Model Development</title>
<p>The model-building approach was based on recommendations from the Food and Drug Administration’s <italic>Guidance for Industry Population Pharmacokinetics</italic>.<sup><xref ref-type="bibr" rid="bibr8-0091270010396373">8</xref></sup> All data preparation and graphical presentation were performed using S-PLUS 6.2. All pharmacokinetic analyses were implemented using the first-order method within the computer program NONMEM 5.1.1.<sup><xref ref-type="bibr" rid="bibr9-0091270010396373">9</xref></sup></p>
<p>In the exploratory data analysis, plots of plasma concentration versus time since the first dose and time since the last dose were generated for each study. Continuous covariates were plotted against subject number to identify any outliers, as well as against each other to identify correlations. Box plots of continuous covariates sorted by categorical covariates were also plotted to identify any potential relationships.</p>
</sec>
<sec id="section4-0091270010396373">
<title>Structural Models</title>
<p>A structural model was developed consistent with the known elimination pathways for CS-917 and its metabolites. CS-917 is rapidly metabolized to R-134550, an inactive metabolite, which is in turn metabolized to R-125338, the active metabolite. R-125338 is eliminated by renal excretion, as well as N-acetylation, to an inactive metabolite, R-143047.</p>
<p>In sum, 1-, 2-, and 3-compartment structural models were evaluated, as necessary, based on graphical evaluations of plasma concentration versus time profiles for CS-917, R-134450, R-125338, and R-143047. Intersubject variability was modeled for all pharmacokinetic parameters as follows:</p>
<p>
<disp-formula id="disp-formula1-0091270010396373">
<label>(1)</label>
<mml:math display="block" id="math1-0091270010396373">
<mml:msub>
<mml:mi>θ</mml:mi>
<mml:mi>i</mml:mi>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mi>θ</mml:mi>
<mml:mrow>
<mml:mi>t</mml:mi>
<mml:mi>y</mml:mi>
<mml:mi>p</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>c</mml:mi>
<mml:mi>a</mml:mi>
<mml:mi>l</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>⋅</mml:mo>
<mml:msup>
<mml:mi>e</mml:mi>
<mml:mrow>
<mml:mi>η</mml:mi>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msup>
<mml:mo>,</mml:mo>
</mml:math>
<graphic alternate-form-of="disp-formula1-0091270010396373" xlink:href="10.1177_0091270010396373-eq1.tif"/></disp-formula>
</p>
<p>where θ<sub><italic>i</italic></sub> is the parameter for the <italic>i</italic><sup><italic>th</italic></sup> subject, θ<sub><italic>typical</italic></sub> is the typical value of the parameter in the population, and η<sub><italic>i</italic></sub> is a random intersubject effect with mean 0 and variance ω<sup>2</sup> (η is referred to as ETA hereafter). ETAs with large coefficients of variation such that the 95% confidence interval included zero were removed from the model during the model development process.</p>
<p>Residual variability was initially assumed to have an additive component and a component proportional to the prediction and was modeled as follows:</p>
<p>
<disp-formula id="disp-formula2-0091270010396373">
<label>(2)</label>
<mml:math display="block" id="math2-0091270010396373">
<mml:msub>
<mml:mi>y</mml:mi>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mover accent="true">
<mml:mi>y</mml:mi>
<mml:mo>^</mml:mo>
</mml:mover>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>⋅</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mi>ε</mml:mi>
<mml:mrow>
<mml:mn>1</mml:mn>
<mml:mi>i</mml:mi>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mi>ε</mml:mi>
<mml:mrow>
<mml:mn>2</mml:mn>
<mml:mi>i</mml:mi>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>,</mml:mo>
</mml:math>
<graphic alternate-form-of="disp-formula2-0091270010396373" xlink:href="10.1177_0091270010396373-eq2.tif"/>
</disp-formula>
</p>
<p>where <italic>y</italic><sub><italic>ij</italic></sub> and <inline-formula id="inline-formula1-0091270010396373">
<mml:math display="inline" id="math3-0091270010396373">
<mml:msub>
<mml:mover accent="true">
<mml:mi>y</mml:mi>
<mml:mo>^</mml:mo>
</mml:mover>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
</mml:math>
</inline-formula> represent the <italic>j</italic><sup><italic>th</italic></sup> observed and predicted concentration, respectively, for the <italic>i</italic><sup><italic>th</italic></sup> subject, and ε is the random residual effect. Each ε is normally distributed with mean 0 and variance σ<sup>2</sup>. Reduction of the residual error model to a simpler form was tested during the model development process.</p>
<p>The structural model was developed in a stepwise manner, starting with the development of a model for CS-917 and sequentially adding in each metabolite, R-134450, R-125338, and R-143047. Each step was conditional on the previous step in the analysis, meaning that at each step, parameters from the previous step were fixed to their estimated values. The structural model was selected on the basis of a change in the objective function value (−2 times the log likelihood) and assessment of diagnostic plots. Outliers, identified as those observations with absolute weighted residuals greater than 6, were excluded from the data set, and the structural model was reassessed using the reduced data set.</p>
</sec>
<sec id="section5-0091270010396373">
<title>Covariate Analysis</title>
<p>Covariate selection was conducted sequentially for each moiety. Demographic variables and laboratory markers were evaluated as covariates on apparent clearances of CS-917, R-1334450, R-125338, and R-143047, while demographic variables were evaluated as covariates on apparent volumes of the central compartment. Taking the drug with or without food was evaluated as a covariate on absorption parameters, including the absorption rate constant (k<sub>a</sub>) and the absorption lag time (T<sub>lag</sub>) for CS-917 and relative bioavailability (F) for all 4 moieties.</p>
<p>Initially, parameter-covariate relationships were examined graphically and using linear regression (for continuous covariates) or analysis of variance (for categorical covariates). Significant parameter-covariate relationships (<italic>P</italic> &lt; .05) thus identified were included in a full tentative pharmacokinetic model. Next, all other parameter-covariates were screened in the final tentative model. All significant relationships were included in the model, and backward elimination (<italic>P</italic> &lt; .01) was used to identify the final model.</p>
<p>Confidence intervals were estimated for each population parameter as <italic>P</italic> ± <italic>Z</italic> · (<italic>SE</italic>), where <italic>P</italic> is a population parameter estimate, <italic>SE</italic> is its associated standard error, and <italic>Z</italic> is the interval coefficient for a standardized normal distribution (<italic>Z</italic> = 1.96 for a 95% confidence interval). Parameter-covariate relationships for which the 95% confidence interval included zero, as well as biologically implausible relationships, were removed from the model. Once this process was complete, the resultant model was considered the final population pharmacokinetic model.</p>
<p>Continuous covariates were included in the model as follows:</p>
<p>
<disp-formula id="disp-formula3-0091270010396373">
<label>(3)</label>
<mml:math display="block" id="math4-0091270010396373">
<mml:msub>
<mml:mi>θ</mml:mi>
<mml:mi>i</mml:mi>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mi>θ</mml:mi>
<mml:mrow>
<mml:mi>T</mml:mi>
<mml:mi>y</mml:mi>
<mml:mi>p</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>c</mml:mi>
<mml:mi>a</mml:mi>
<mml:mi>l</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>⋅</mml:mo>
<mml:msup>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mrow>
<mml:mfrac>
<mml:mrow>
<mml:mi>C</mml:mi>
<mml:mi>o</mml:mi>
<mml:msub>
<mml:mi>v</mml:mi>
<mml:mi>i</mml:mi>
</mml:msub>
</mml:mrow>
<mml:mrow>
<mml:mi>C</mml:mi>
<mml:mi>o</mml:mi>
<mml:msub>
<mml:mi>v</mml:mi>
<mml:mrow>
<mml:mi>m</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>d</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>a</mml:mi>
<mml:mi>n</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:mfrac>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:msub>
<mml:mi>θ</mml:mi>
<mml:mrow>
<mml:mi>e</mml:mi>
<mml:mi>f</mml:mi>
<mml:mi>f</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:msup>
</mml:math>
<graphic alternate-form-of="disp-formula3-0091270010396373" xlink:href="10.1177_0091270010396373-eq3.tif"/></disp-formula>
</p>
<p>where θ<sub><italic>i</italic></sub> is the value of the parameter for the <italic>i</italic><sup><italic>th</italic></sup> individual, θ<sub><italic>Typical</italic></sub> is the typical value of the parameter in the population, <italic>Cov</italic><sub><italic>i</italic></sub> is the value of the covariate for the individual, <italic>Cov</italic><sub><italic>median</italic></sub> is the median value of the covariate in the study population, and θ<sub><italic>eff</italic></sub> is the effect of the covariate on the parameter.</p>
<p>Categorical covariates were introduced in the model as follows:</p>
<p>
<disp-formula id="disp-formula4-0091270010396373">
<label>(4)</label>
<mml:math display="block" id="math5-0091270010396373">
<mml:msub>
<mml:mi>θ</mml:mi>
<mml:mi>i</mml:mi>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mi>θ</mml:mi>
<mml:mi>T</mml:mi>
</mml:msub>
<mml:mo>⋅</mml:mo>
<mml:mi>exp</mml:mi>
<mml:mspace width="0.25em"/>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>C</mml:mi>
<mml:mi>o</mml:mi>
<mml:msub>
<mml:mi>v</mml:mi>
<mml:mi>i</mml:mi>
</mml:msub>
<mml:mo>⋅</mml:mo>
<mml:msub>
<mml:mi>θ</mml:mi>
<mml:mrow>
<mml:mi>e</mml:mi>
<mml:mi>f</mml:mi>
<mml:mi>f</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>,</mml:mo>
</mml:math>
<graphic alternate-form-of="disp-formula4-0091270010396373" xlink:href="10.1177_0091270010396373-eq4.tif"/>
</disp-formula>
</p>
<p>where <italic>Cov</italic><sub><italic>i</italic></sub> is an indicator variable representing one form of the categorical variable (eg, men coded as 0 and women as 1) and θ<sub><italic>eff</italic></sub> is the effect of the covariate on the parameter.</p>
</sec>
<sec id="section6-0091270010396373">
<title>Model Assessment</title>
<p>Population predicted values and individual predicted values versus observed concentrations were examined to determine if the model adequately described the data. Residuals versus time and residuals versus predicted concentrations were examined to determine if a model bias existed. Relationships between structural model parameters and covariates were examined graphically, after accounting for all statistically significant covariate relationships to determine if any trends still existed.</p>
<p>A visual predictive check was used to verify that the models adequately described the central tendency and spread of the data.<sup><xref ref-type="bibr" rid="bibr10-0091270010396373">10</xref></sup> Based on this approach, plots of actual data were overlaid with model predictions (mean, 90% confidence interval) to determine the fraction of data that lie within the model prediction interval.</p>
</sec>
<sec id="section7-0091270010396373">
<title>Simulations</title>
<p>Simulation of the final pharmacokinetic model under different covariate scenarios was performed to determine whether any of the covariates retained in the final model had a clinically significant impact on R-125338 exposure. Beginning with a base case of a white male patient with typical covariate values, each covariate was changed one by one, and a simulation of 400 patients at steady state, receiving 100 mg CS-917 daily, was rerun with the same random seed.</p>
<p>The impact of renal impairment on R-125338 exposure was similarly investigated. The simulation included 200 patients in each of 4 renal function categories: normal renal function (CLCR &gt; 80 mL/min), mild impairment (CLCR = 50-80 mL/min), moderate impairment (CLCR = 30-50 mL/min), and severe impairment (CLCR = 10-30 mL/min).<sup><xref ref-type="bibr" rid="bibr11-0091270010396373">11</xref></sup> Plasma concentrations of R-125338 following steady state doses of 100 mg CS-917 daily were simulated for all 800 patients using the same random seed.</p>
<p>R-125338 exposures, including AUC<sub>ss,0-12</sub> and C<sub>max,ss</sub>, were calculated and summarized using descriptive statistics.</p>
</sec>
<sec id="section8-0091270010396373">
<title>Model for R-125338</title>
<p>For comparison, a model was developed for the active moiety. The model development and assessment processes were similar to those already described; however, only R-125338 observations were analyzed. In this model, the oral bioavailability parameter reflected formation of R-125338 from the bioavailable fraction of the orally administered dose of prodrug CS-917. Simulations were compared with those for the final pharmacokinetic model for the parent and metabolites to evaluate the utility of the simpler model.</p>
</sec>
</sec>
<sec id="section9-0091270010396373" sec-type="results">
<title>Results</title>
<p><xref ref-type="table" rid="table2-0091270010396373">Table II</xref> summarizes the baseline characteristics for patients in the pharmacokinetic data set. Approximately 60% were non-Hispanic white men. The mean age was 58 years and the mean body weight was 87 kg. Patients had primarily normal renal and hepatic function, and there was not a wide variation in these terms within the population. Exploratory graphical evaluations of the data set (noncompartmental analysis including steady-state doses up to 400 mg twice daily) showed dose proportionality. The overall pharmacokinetics appear to be linear as dose-normalized plasma concentration–time profiles, and apparent clearance calculations did not reveal any trends with dose level (see <xref ref-type="fig" rid="fig1-0091270010396373">Figure 1</xref> of the online appendix, available at <ext-link ext-link-type="uri" xlink:href="http://jcp.sagepub.com/supplemental/">http://jcp.sagepub.com/supplemental/</ext-link>).</p>
<table-wrap id="table2-0091270010396373" position="float">
<label>Table II</label>
<caption><p>Demographic and Baseline Characteristics of the Pharmacokinetic Dataset</p></caption>
<graphic alternate-form-of="table2-0091270010396373" xlink:href="10.1177_0091270010396373-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Characteristic</th>
<th align="center">Mean ± SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>58 ± 9</td>
</tr>
<tr>
<td>Body weight, kg</td>
<td>87 ± 16</td>
</tr>
<tr>
<td>Body mass index, kg/m<sup>2</sup></td>
<td>31 ± 5</td>
</tr>
<tr>
<td>Alanine aminotransferase, IU/L</td>
<td>27 ± 12</td>
</tr>
<tr>
<td>Aspartate aminotransferase, IU/L</td>
<td>21 ± 7</td>
</tr>
<tr>
<td>Total bilirubin, mg/dL</td>
<td>0.69 ± 0.26</td>
</tr>
<tr>
<td>Creatinine clearance, mL/min</td>
<td>73 ± 20</td>
</tr>
<tr>
<th align="left">Patients</th>
<th align="center">n</th>
</tr>
<tr>
<td><italic>Sex</italic>: men, women</td>
<td>90, 51</td>
</tr>
<tr>
<td><italic>Race</italic>: white, black, Hispanic</td>
<td>87, 19, 35</td>
</tr>
<tr>
<td><italic>Food</italic>: tablet with food, fasted capsule</td>
<td>109, 32</td>
</tr>
</tbody>
</table>
</table-wrap>
<sec id="section10-0091270010396373">
<title>Structural Model Development</title>
<p><xref ref-type="fig" rid="fig1-0091270010396373">Figure 1</xref> presents the full population pharmacokinetic model. For CS-917, a 1-compartment model with first-order elimination, first-order absorption, and an absorption lag time provided a reasonable fit to the data. There was not a substantive improvement in the objective function value or in the visual goodness of fit with the addition of a second (peripheral) compartment (objective function value, 14337.4 for 1-compartment model vs 14333.2 for 2-compartment model). Apparent clearance (CL/F) and apparent volume of the central compartment (V<sub>c</sub>/F) were expressed relative to the oral bioavailability of CS-917, which is not identifiable following oral dose administration.</p>
<fig id="fig1-0091270010396373" position="float">
<label>Figure 1.</label>
<caption><p>Final pharmacokinetic model showing metabolism pathways. F reflects oral bioavailability for CS-917 and both oral bioavailability and fraction metabolized for R-134450, R-125338, and R-143047.</p></caption>
<graphic xlink:href="10.1177_0091270010396373-fig1.tif"/>
</fig>
<p>A 2-compartment model with first-order formation from CS-917 and first-order elimination described the R-134450 plasma concentration versus time data, with negligible improvement with the addition of a third compartment. Based on the results of a separate compartmental analysis of R-125338 data alone and graphical evaluations, a 2-compartment model with first-order formation from R-134450 and first-order elimination was fit to the R-125338 plasma concentration versus time data. For R-143047, a 1-compartment model with first-order formation from R-125338 and first-order elimination provided a reasonable fit to the data. No improvement was gained from the addition of a second compartment.</p>
<p>For each metabolite, apparent clearance terms (CL/F and Q/F) and apparent volume of distribution terms (V<sub>c</sub>/F and V<sub>p</sub>/F) were expressed relative to the oral bioavailability of CS-917 and the fraction of CS-917 metabolized to moiety of interest, neither of which were known.</p>
<p>Interindividual variability was estimated for all structural pharmacokinetic model parameters. Residual error was modeled with proportional and additive terms for each of the 4 moieties.</p>
<p>Diagnostic plots for the base model showed a reasonable fit of the model to the data with no apparent trends of residuals over time or model predictions (plots not shown). Examination of residual plots showed a small number of observations associated with large absolute weighted residuals. Exclusion of these 14 observations reduced the magnitude of the residual error terms without influencing the structural form of the model.</p>
</sec>
<sec id="section11-0091270010396373">
<title>Covariate Models</title>
<p>For the 1-compartment CS-917 base model, graphical evaluations showed statistically significant (<italic>P</italic> &lt; .05) effects of sex, body weight, alanine aminotransferase, and total bilirubin on CL/F. These covariates, with an effect of food on oral bioavailability, were included in a full model, and a backward elimination process was used to identify covariates that did not significantly influence the pharmacokinetic of CS-917 (<italic>P</italic> &lt; .01). During backward selection, only body weight on CL/F and food on oral bioavailability remained statistically significant. Next, all other covariates were tested on CL/F and V<sub>c</sub>/F. Significant effects were included in a full model, and backward selection was again used to obtain the final model. This process identified an effect of body weight on V<sub>c</sub>/F. Therefore, the final model for CS-917 included effects of body weight on CL/F and V<sub>c</sub>/F and an effect of food on the relative oral bioavailability. Under this model and with all other variables remaining unchanged, a 10% increase in body weight would increase CL/F by 9.5% and increase V<sub>c</sub>/F by 6.3%. Administering the oral tablet with food would result in 24% lower relative bioavailability than would the administration of the capsule under fasted conditions.</p>
<p>For the 2-compartment R-125338 base model, body weight, body mass index, creatinine clearance, food, and race were significant for CL/F, whereas body mass index was significant for V<sub>c</sub>/F (<italic>P</italic> &lt; .05). Body mass index was chosen over body weight for inclusion in the full model for CL/F to be consistent with the model for Vc/F. During backward selection from the full model, only creatinine clearance and food on CL/F remained statistically significant. Next, all other covariates (including body weight) were tested on CL/F and V<sub>c</sub>/F. Significant effects were included in a full model, and backward selection was again used to obtain the final model. This process identified an effect of black race on V<sub>c</sub>/F. Therefore, the final model for R-125338 included effects of creatinine clearance and food on CL/F and an effect of black race on V<sub>c</sub>/F.</p>
<p>Evaluation of diagnostic plots revealed a high estimate of R-125338 CL/F for 1 patient with a high creatinine clearance (144 mL/min). The final model was reestimated after exclusion of this patient to evaluate the impact, if any, of the patient on parameter estimation. Similar parameter estimates were obtained for the final model after exclusion of the patient (not shown).</p>
<p>Under this model and with all other variables remaining unchanged, a 10% decrease in renal function, as measured by creatinine clearance, would decrease apparent clearance of R-125338 by 3.5%, while administration of the oral tablet with food would result in 20% lower apparent clearance compared with administration of the capsule under fasted conditions. Patients of black race would have a 43% reduction in apparent volume of distribution.</p>
<p>For the 2-compartment R-134450 base model, sex and race were significant for CL/F, while sex and food were significant for V<sub>c</sub>/F (<italic>P</italic> &lt; .05). These covariates were included in a full model. During backward selection, the effect of food was dropped from the final tentative model. Next, all other covariates were screened on CL/F and V<sub>c</sub>/F, and significant effects were included in a full model. Backward selection was again used to obtain the final model. After exclusion of nonsignificant effects, the final model for R-134450 included effects of age and black race on CL/F. Under this model and with all other variables remaining unchanged, a 10% increase in age would decrease apparent clearance by 5.5%, and patients of black race would have a 31% lower apparent clearance than others. However, while statistically significant, both effects were associated with large imprecision (~45%) in the estimates.</p>
<p>For the 1-compartment R-143047 base model, all covariates were included in a full model. During backward selection, all covariate terms with relatively large standard errors were dropped from the final tentative model. At this step, only body weight on CL/F and sex on V<sub>c</sub>/F remained in the model. Stepwise addition was conducted for selected other covariates, including demographics, food, and creatinine clearance as a marker of renal function, but none were well estimated enough to merit inclusion. Therefore, the final model for R-143047 included the effect of body weight on CL/F and the effect of sex on V<sub>c</sub>/F. Under this model and with all other variables remaining unchanged, a 10% increase in body weight would increase apparent clearance by 6.1%, and female patients would have a 25% lower apparent volume of distribution than males.</p>
<p><xref ref-type="table" rid="table3-0091270010396373">Table III</xref> shows parameter estimates for the final linked population pharmacokinetic model. Diagnostic plots for the final linked population pharmacokinetic model show that the predicted concentrations matched the observed concentrations satisfactorily and that residual errors were approximately normally distributed over time and predicted concentration for all moieties (see <xref ref-type="fig" rid="fig2-0091270010396373">Figure 2</xref> and <xref ref-type="fig" rid="fig3-0091270010396373">Figure 3</xref> showing diagnostic plots for prodrug and active moiety; otherwise see online appendix). Relationships among parameters and covariates were evaluated after inclusion of all significant parameter-covariate relationships in the model (see online appendix). These plots indicate that the covariate model adequately describes relationships between individual parameter estimates and important covariates.</p>
<table-wrap id="table3-0091270010396373" position="float">
<label>Table III</label>
<caption><p>Population Pharmacokinetic Parameters for the Linked Model and for R-125338 Alone: Estimate (%CV)</p></caption>
<graphic alternate-form-of="table3-0091270010396373" xlink:href="10.1177_0091270010396373-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="4">Linked Model</th>
<th align="center">Single Moiety</th>
</tr>
<tr>
<th align="left">Parameter</th>
<th align="center">CS-917</th>
<th align="center">R-125338</th>
<th align="center">R-134450</th>
<th align="center">R-143047</th>
<th align="center">R-125338</th>
</tr>
</thead>
<tbody>
<tr>
<td>CL/F (L/h)</td>
<td>85.1 (8)</td>
<td>30.9 (7)</td>
<td>187 (15)</td>
<td>9.81 (7)</td>
<td>35.3 (4)</td>
</tr>
<tr>
<td>V<sub>c</sub>/F (L)</td>
<td>68.0 (9)</td>
<td>60.7 (10)</td>
<td>50.7 (30)</td>
<td>338 (8)</td>
<td>187 (6)</td>
</tr>
<tr>
<td>Q/F (L/h)</td>
<td align="center">—</td>
<td>7.07 (14)</td>
<td>197 (11)</td>
<td align="center">—</td>
<td>5.61 (11)</td>
</tr>
<tr>
<td>V<sub>p</sub>/F (L)</td>
<td align="center">—</td>
<td>278 (7)</td>
<td>249 (9)</td>
<td align="center">—</td>
<td>313 (6)</td>
</tr>
<tr>
<td>k<sub>a</sub> (L/h)</td>
<td>5.40 (21)</td>
<td align="center">—</td>
<td align="center">—</td>
<td align="center">—</td>
<td>2.54 (17)</td>
</tr>
<tr>
<td>T<sub>lag</sub> (h)</td>
<td>0.23 (3)</td>
<td align="center">—</td>
<td align="center">—</td>
<td align="center">—</td>
<td>0.46 (1)</td>
</tr>
<tr>
<td colspan="6">Effect</td>
</tr>
<tr>
<td> Body weight on CL/F</td>
<td>0.95 (24)</td>
<td align="center">—</td>
<td align="center">—</td>
<td>0.61 (34)</td>
<td align="center">—</td>
</tr>
<tr>
<td> CLCR on CL/F</td>
<td align="center">—</td>
<td>0.36 (27)</td>
<td align="center">—</td>
<td align="center">—</td>
<td>0.37 (23)</td>
</tr>
<tr>
<td> Age on CL/F</td>
<td align="center">—</td>
<td align="center">—</td>
<td>−0.55 (45)</td>
<td align="center">—</td>
<td/>
</tr>
<tr>
<td> Female sex on CL/F</td>
<td align="center">—</td>
<td align="center">—</td>
<td align="center">—</td>
<td>−0.28 (45)</td>
<td/>
</tr>
<tr>
<td> Food on CL/F</td>
<td align="center">—</td>
<td>−0.22 (37)</td>
<td align="center">—</td>
<td align="center">—</td>
<td align="center">—</td>
</tr>
<tr>
<td> Food on relative F</td>
<td>−0.27 (40)</td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> Black race on CL/F</td>
<td align="center">—</td>
<td align="center">—</td>
<td>−0.37 (46)</td>
<td align="center">—</td>
<td/>
</tr>
<tr>
<td> Body weight on V<sub>c</sub>/F</td>
<td>0.63 (45)</td>
<td align="center">—</td>
<td align="center">—</td>
<td align="center">—</td>
<td align="center">—</td>
</tr>
<tr>
<td> Black race on V<sub>c</sub>/F</td>
<td align="center">—</td>
<td>−0.56 (30)</td>
<td align="center">—</td>
<td align="center">—</td>
<td align="center">—</td>
</tr>
<tr>
<td> Food on k<sub>a</sub></td>
<td align="center">—</td>
<td align="center">—</td>
<td align="center">—</td>
<td align="center">—</td>
<td>−1.07 (25)</td>
</tr>
<tr>
<td colspan="6">Interindividual variability</td>
</tr>
<tr>
<td> CL/F</td>
<td>0.20 (21)</td>
<td>0.14 (19)</td>
<td>0.95 (57)</td>
<td>0.36 (27)</td>
<td>0.12 (14)</td>
</tr>
<tr>
<td> V<sub>c</sub>/F</td>
<td>0.16 (36)</td>
<td>0.72 (22)</td>
<td>1.37 (49)</td>
<td>0.25 (30)</td>
<td>0.19 (18)</td>
</tr>
<tr>
<td> Q/F</td>
<td align="center">—</td>
<td>0.44 (23)</td>
<td>0.39 (63)</td>
<td align="center">—</td>
<td>0.34 (20)</td>
</tr>
<tr>
<td> Vp/F</td>
<td align="center">—</td>
<td>0.19 (23)</td>
<td>0.60 (30)</td>
<td align="center">—</td>
<td>0.17 (25)</td>
</tr>
<tr>
<td> K<sub>a</sub></td>
<td>0.94 (45)</td>
<td align="center">—</td>
<td align="center">—</td>
<td align="center">—</td>
<td>0.52 (26)</td>
</tr>
<tr>
<td> T<sub>lag</sub></td>
<td>0.01 (95)</td>
<td align="center">—</td>
<td align="center">—</td>
<td align="center">—</td>
<td align="center">—</td>
</tr>
<tr>
<td colspan="6">Residual error</td>
</tr>
<tr>
<td> Proportional</td>
<td>0.28 (14)</td>
<td>0.07 (12)</td>
<td>0.15 (28)</td>
<td>0.02 (20)</td>
<td>0.08 (11)</td>
</tr>
<tr>
<td> Additive</td>
<td>1620 (38)</td>
<td>13.7 (38)</td>
<td>146 (20)</td>
<td>271 (36)</td>
<td>9.63 (40)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0091270010396373">
<p>%CV, coefficient of variation of the estimate (absolute value of 100*SE/estimate). Dashes (—) indicate <italic>not applicable</italic>. Final covariate models for CS-917 were parameterized as follows:</p>
<p>
<inline-formula id="inline-formula2-0091270010396373">
<mml:math display="inline" id="math6-0091270010396373">
<mml:mi>C</mml:mi>
<mml:mi>L</mml:mi>
<mml:mo stretchy="false">/</mml:mo>
<mml:mi>F</mml:mi>
<mml:mo>=</mml:mo>
<mml:mn>85</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>⋅</mml:mo>
<mml:msup>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mrow>
<mml:mfrac>
<mml:mrow>
<mml:mi>W</mml:mi>
<mml:mi>T</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>86</mml:mn>
</mml:mrow>
</mml:mfrac>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>95</mml:mn>
</mml:mrow>
</mml:msup>
<mml:mo>;</mml:mo>
<mml:msub>
<mml:mi>V</mml:mi>
<mml:mi>c</mml:mi>
</mml:msub>
<mml:mo stretchy="false">/</mml:mo>
<mml:mi>F</mml:mi>
<mml:mo>=</mml:mo>
<mml:mn>68</mml:mn>
<mml:mo>⋅</mml:mo>
<mml:msup>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mrow>
<mml:mfrac>
<mml:mrow>
<mml:mi>W</mml:mi>
<mml:mi>T</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>86</mml:mn>
</mml:mrow>
</mml:mfrac>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>63</mml:mn>
</mml:mrow>
</mml:msup>
<mml:mo>;</mml:mo>
<mml:mi>F</mml:mi>
<mml:mo>=</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>⋅</mml:mo>
<mml:mi>exp</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mo>−</mml:mo>
<mml:mn>0</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>27</mml:mn>
<mml:mo>⋅</mml:mo>
<mml:msub>
<mml:mi>K</mml:mi>
<mml:mrow>
<mml:mi>F</mml:mi>
<mml:mi>o</mml:mi>
<mml:mi>o</mml:mi>
<mml:mi>d</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>.</mml:mo>
</mml:math>
</inline-formula>
</p>
</fn>
<fn id="table-fn3-0091270010396373">
<p>Final covariate models for R-125338 were parameterized as follows:</p>
<p>
<inline-formula id="inline-formula3-0091270010396373">
<mml:math display="inline" id="math7-0091270010396373">
<mml:mi>C</mml:mi>
<mml:mi>L</mml:mi>
<mml:mo stretchy="false">/</mml:mo>
<mml:mi>F</mml:mi>
<mml:mo>=</mml:mo>
<mml:mn>30</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>9</mml:mn>
<mml:mo>⋅</mml:mo>
<mml:msup>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mrow>
<mml:mfrac>
<mml:mrow>
<mml:mi>C</mml:mi>
<mml:mi>L</mml:mi>
<mml:mi>C</mml:mi>
<mml:mi>R</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>70</mml:mn>
</mml:mrow>
</mml:mfrac>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>36</mml:mn>
</mml:mrow>
</mml:msup>
<mml:mo>⋅</mml:mo>
<mml:mi>exp</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mo>−</mml:mo>
<mml:mn>0</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>22</mml:mn>
<mml:mo>⋅</mml:mo>
<mml:msub>
<mml:mi>K</mml:mi>
<mml:mrow>
<mml:mi>F</mml:mi>
<mml:mi>o</mml:mi>
<mml:mi>o</mml:mi>
<mml:mi>d</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>;</mml:mo>
<mml:msub>
<mml:mi>V</mml:mi>
<mml:mi>c</mml:mi>
</mml:msub>
<mml:mo stretchy="false">/</mml:mo>
<mml:mi>F</mml:mi>
<mml:mo>=</mml:mo>
<mml:mn>60</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>7</mml:mn>
<mml:mo>⋅</mml:mo>
<mml:mi>exp</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mo>−</mml:mo>
<mml:mn>0</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>56</mml:mn>
<mml:mo>⋅</mml:mo>
<mml:msub>
<mml:mi>K</mml:mi>
<mml:mrow>
<mml:mi>B</mml:mi>
<mml:mi>l</mml:mi>
<mml:mi>a</mml:mi>
<mml:mi>c</mml:mi>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>,</mml:mo>
</mml:math>
</inline-formula></p>
<p>where WT is body weight, <italic>K</italic><sub><italic>Food</italic></sub> = 1 for tablet with food and <italic>K</italic><sub><italic>Black</italic></sub> = 1 for black race.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="fig2-0091270010396373" position="float">
<label>Figure 2.</label>
<caption><p>Goodness of fit plots for CS-917 in the final pharmacokinetic model. Plots of observed plasma concentrations versus population values predicted by the model (upper left panel) and observed plasma concentrations versus individual model-predicted concentrations (upper right panel). Units of plasma concentration are ng/mL for observed and predicted values; the black line is the line of unity; and the gray line is a loess smooth. Plots of weighted residuals versus model-predicted concentrations (lower left panel) and weighted residuals versus time (lower right panel).</p></caption>
<graphic xlink:href="10.1177_0091270010396373-fig2.tif"/>
</fig>
<fig id="fig3-0091270010396373" position="float">
<label>Figure 3.</label>
<caption><p>Goodness of fit plots for R-125338 in the final pharmacokinetic model. Plots of observed plasma concentrations versus population values predicted by the model (upper left panel) and observed plasma concentrations versus individual model-predicted concentrations (upper right panel). Units of plasma concentration are ng/mL for observed and predicted values; the black line is the line of unity; and the gray line is a loess smooth. Plots of weighted residuals versus model-predicted concentrations (lower left panel) and weighted residuals versus time (lower right panel).</p></caption>
<graphic xlink:href="10.1177_0091270010396373-fig3.tif"/>
</fig>
<p>There were no effects of liver function tests detected on the pharmacokinetics of any of the 4 moieties. However, as all patients in the data set were within normal range of liver function, this finding should not be assumed to hold for those outside the normal range.</p>
</sec>
<sec id="section12-0091270010396373">
<title>Model Qualification</title>
<p>Model qualification plots show that the final pharmacokinetic model adequately captured the central tendency of the data (<xref ref-type="fig" rid="fig4-0091270010396373">Figure 4</xref>; 200 mg twice daily regimens are shown). In addition, the spread of the data was captured for R-125338, for which 92% of the data lie within the 90% confidence bounds. In comparison, 84% and 95% of the data lie within the 90% confidence bounds for CS-917 and R-134450, respectively.</p>
<fig id="fig4-0091270010396373" position="float">
<label>Figure 4.</label>
<caption><p>Visual predictive check for the 200 mg twice daily dose in study 1B using (A) linked compartmental model and (B) model for R-125338 only. Lines represent the median and 90% prediction interval in each plot. Limit of quantitation was 5 ng/mL.</p></caption>
<graphic xlink:href="10.1177_0091270010396373-fig4.tif"/>
</fig>
</sec>
<sec id="section13-0091270010396373">
<title>Simulations</title>
<p>Of the covariates included in the final pharmacokinetic model, only CLCR had a clinically significant impact on R-125338 AUC<sub>0-12,ss</sub> over the ranges tested. Halving CLCR from 70 mL/min for the typical patient to 35 mL/min resulted in a 27% increase in R-125338 exposure. Varying the other covariates had less than a 5% impact on exposure.</p>
<p><xref ref-type="table" rid="table4-0091270010396373">Table IV</xref> shows steady-state exposures of R-125338 for a theoretical renal impairment study. In patients with moderate renal impairment (CLCR = 30 to 50 mL/min), R-125338 C<sub>max,ss</sub> and AUC<sub>ss,0-12</sub> increased 30% and 50%, respectively, relative to patients with normal renal function (&gt; 80 mL/min).</p>
<table-wrap id="table4-0091270010396373" position="float">
<label>Table IV</label>
<caption><p>Pharmacokinetic Simulation Results for a Renal Impairment Study by Renal Function Category</p></caption>
<graphic alternate-form-of="table4-0091270010396373" xlink:href="10.1177_0091270010396373-table4.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center">C<sub>max</sub> (ng/mL)</th>
<th align="center">AUC<sub>ss,0-12</sub> (ng·h/mL)</th>
</tr>
<tr>
<th align="left">Creatinine Clearance, mL/min</th>
<th align="center">Mean (SEM)</th>
<th align="center">Mean (SEM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>80-120</td>
<td>448 (17)</td>
<td>3020 (81)</td>
</tr>
<tr>
<td>50-80</td>
<td>535 (24)</td>
<td>3520 (83)</td>
</tr>
<tr>
<td>30-50</td>
<td>598 (24)</td>
<td>4480 (115)</td>
</tr>
<tr>
<td>&lt; 30</td>
<td>636 (23)</td>
<td>5530 (142)</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="section14-0091270010396373">
<title>Analysis of R-125338 Only</title>
<p>For comparison, <xref ref-type="table" rid="table3-0091270010396373">Table III</xref> shows parameter estimates for the fit of R-125338 data alone. The model qualification analysis (see online appendix) showed that this minimal model captured the central tendency of the data and the spread of the data for R-125338, with 84% of the data lying within the 90% confidence bounds. Although the linked compartmental model was somewhat better in characterizing peak plasma concentrations of R-125338, correlation between individual R-125338 predictions for the minimal model and the linked compartmental model was .989 (<xref ref-type="fig" rid="fig5-0091270010396373">Figure 5</xref>). Simulations of the impact of covariates in the final model showed that only CLCR had a clinically significant impact on R-125338 AUC<sub>ss,0-12</sub>, similar in magnitude to that observed for the linked compartmental model (31% compared with 27%), while the effect of food had a negligible impact on exposure.</p>
<fig id="fig5-0091270010396373" position="float">
<label>Figure 5.</label>
<caption><p>Correlation between individual R-125338 predictions from the 2 models developed in this analysis.</p></caption>
<graphic xlink:href="10.1177_0091270010396373-fig5.tif"/>
</fig>
</sec>
</sec>
<sec id="section15-0091270010396373" sec-type="discussion">
<title>Discussion</title>
<p>The pharmacokinetics of the active hypoglycemic moiety R-125338 from the inactive prodrug CS-917 were characterized. The disposition of 2 other inactive metabolites were also described. A combined linked model was developed to describe the data, with 1 compartment for both CS-917 and R-143047 and with 2 compartments for each of R-125338 and R-134450. Because apparent volumes of the central compartment for each moiety were not identifiable, each step of the analysis was conditioned on the previous step. Based on this approach, significant covariate influences on each moiety were simulated to evaluate the effects on exposure to the active metabolite R-125338, for which apparent clearance was correlated with renal function. This finding is not unexpected given that R-125338 is cleared, in part, by renal excretion.<sup><xref ref-type="bibr" rid="bibr1-0091270010396373">1</xref></sup> In addition, apparent clearance was reduced in the presence of food. This may be interpreted as increased formation of the metabolite in the liver and small intestine when CS-917 is taken with food, perhaps due to increased blood flow to the liver following a meal. The apparent volume of distribution was found to be reduced in patients of black race; however, since black race accounted for only 12% of the patients in the data set, this result remains to be confirmed in a larger data set.</p>
<p>For the prodrug CS-917, apparent clearance and volume of distribution were found to increase with body weight. In this data set, oral bioavailability was reduced for tablet administered with food compared with fasted capsule. However, this result is not consistent with the results of 2 phase I crossover studies in healthy subjects not included in this analysis, which showed increased CS-917 AUC for 200-mg tablet administered with food compared with fasted capsule.<sup><xref ref-type="bibr" rid="bibr1-0091270010396373">1</xref></sup> Nevertheless, patients with diabetes and healthy subjects given the same dose exhibited similar exposures to R-125338, as shown in <xref ref-type="fig" rid="fig6-0091270010396373">Figure 6</xref>. The figure compares AUC<sub>0-24</sub> calculated for healthy subjects from a study not included in this analysis with those estimated in this analysis for diabetic patients, over the dose range of the diabetic data set. Effects of patient-specific R-125338 plasma concentration predictions on glucose metabolism will be described in a separate communication.</p>
<fig id="fig6-0091270010396373" position="float">
<label>Figure 6.</label>
<caption><p>Diabetic patient R-125338 model predictions versus multiple-dose results in healthy patients. Circles are calculated AUC<sub>0-24</sub> for healthy subjects in a study not included in this analysis. Horizontal line within data represents median. Square and triangles to right of data represent mean and 90% variation interval, respectively, estimated for individual diabetic patients in this analysis.</p></caption>
<graphic xlink:href="10.1177_0091270010396373-fig6.tif"/>
</fig>
<p>Simulation of the pharmacokinetic model under different covariate scenarios was performed to determine whether any covariate effect had a clinically significant impact on R-125338 exposure. A simulation of 400 patients at steady state receiving 100 mg CS-917 daily indicated that only CLCR had a clinically significant impact on R-125338 AUC<sub>ss,0-12</sub> over the ranges of covariates tested. Therefore, despite several statistically significant covariates across the linked pharmacokinetic model, only renal impairment, as measured by creatinine clearance, was clinically relevant. This finding confirms the results obtained from fitting just the active metabolite. On this basis, population pharmacokinetic analysis of the active moiety alone was adequate to identify clinically significant covariates and was substantially less time-consuming than that for the linked compartmental model including parent drug and all metabolites.</p>
<p>In summary, estimation of exposure to the active metabolite of the inactive pro-drug CS-917 may be performed using the model developed for the active moiety alone. The apparent clearance of the active metabolite R-125338 was correlated with renal function. In moderate renal impairment, R-125338 exposure is increased by 30% to 50% and may necessitate dosage adjustment.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p>Financial disclosure: Drs Walker and Rohatagi are employees of Daiichi Sankyo, the sponsor of this work. Drs Kastrissios, Carrothers, Kshirsagar, and Khariton are employees of Pharsight Corp, which was contracted by Daiichi Sankyo to work on this analysis. Dr Mager serves as a consultant to Daiichi Sankyo.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0091270010396373">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Meyer</surname><given-names>C</given-names></name>
<name><surname>Stumvoll</surname><given-names>M</given-names></name>
<name><surname>Nadkarni</surname><given-names>V</given-names></name>
<name><surname>Dostou</surname><given-names>J</given-names></name>
<name><surname>Mitrakou</surname><given-names>A</given-names></name>
<name><surname>Gerich</surname><given-names>J</given-names></name>
</person-group>. <article-title>Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus</article-title>. <source>J Clin Invest</source>. <year>1998</year>;<volume>102</volume>:<fpage>619</fpage>-<lpage>624</lpage>.</citation>
</ref>
<ref id="bibr2-0091270010396373">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Meyer</surname><given-names>C</given-names></name>
<name><surname>Woerle</surname><given-names>HJ</given-names></name>
<name><surname>Dostou</surname><given-names>JM</given-names></name>
<name><surname>Welle</surname><given-names>SL</given-names></name>
<name><surname>Gerich</surname><given-names>JE</given-names></name>
</person-group>. <article-title>Abnormal renal, hepatic, and muscle glucose metabolism following glucose ingestion in type 2 diabetes</article-title>. <source>Am J Physiol Endocrinol Metab</source>. <year>2004</year>;<volume>287</volume>:<fpage>E1049</fpage>-<lpage>E1056</lpage>.</citation>
</ref>
<ref id="bibr3-0091270010396373">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hundal</surname><given-names>RS</given-names></name>
<name><surname>Krssak</surname><given-names>M</given-names></name>
<name><surname>Dufour</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Mechanism by which metformin reduces glucose production in type 2 diabetes</article-title>. <source>Diabetes</source>. <year>2000</year>;<volume>49</volume>:<fpage>2063</fpage>-<lpage>2069</lpage>.</citation>
</ref>
<ref id="bibr4-0091270010396373">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Okuno</surname><given-names>A</given-names></name>
<name><surname>Takahashi</surname><given-names>K</given-names></name>
<name><surname>Tanaka</surname><given-names>J</given-names></name>
<name><surname>Yoshida</surname><given-names>T</given-names></name>
</person-group>. <article-title>CS-917, a fructose 1,6-bisphosphatase inhibitor, suppresses gluconeogenesis in human hepatocytes, whereas metformin stimulates glycolysis in Caco-2 cells</article-title>. <source>Diabetes</source>. <year>2007</year>;<volume>56</volume>(<issue>suppl 1</issue>):<fpage>A130</fpage>.</citation>
</ref>
<ref id="bibr5-0091270010396373">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Walker</surname><given-names>JR</given-names></name>
<name><surname>Freudenthaler</surname><given-names>S</given-names></name>
<name><surname>Dmuchowski</surname><given-names>CF</given-names></name>
<etal/>
</person-group>. <article-title>Single and multiple dose pharmacokinetics and pharmacodynamics of a novel FBPase inhibitor, CS917, in healthy subjects</article-title>. <source>J Clin Pharmacol</source>. <year>2006</year>;<volume>46</volume>:<issue>1069</issue>.</citation>
</ref>
<ref id="bibr6-0091270010396373">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Triscari</surname><given-names>J</given-names></name>
<name><surname>Walker</surname><given-names>J</given-names></name>
<name><surname>Feins</surname><given-names>K</given-names></name>
<name><surname>Tao</surname><given-names>B</given-names></name>
<name><surname>Simon</surname><given-names>R</given-names></name>
</person-group>. <article-title>Multiple ascending doses of CS-917, a novel fructose 1,6-bisphosphatase (FBPase) inhibitor, in subjects with type 2 diabetes treated for 14 days</article-title>. <source>Diabetes</source>. <year>2006</year>;<volume>55</volume>(<issue>suppl 1</issue>):<fpage>A105</fpage>-<lpage>A106</lpage>.</citation>
</ref>
<ref id="bibr7-0091270010396373">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cockcroft</surname><given-names>DW</given-names></name>
<name><surname>Gault</surname><given-names>MH</given-names></name>
</person-group>. <article-title>Prediction of creatinine clearance from serum creatinine</article-title>. <source>Nephron</source>. <year>1976</year>;<volume>16</volume>:<fpage>31</fpage>-<lpage>41</lpage>.</citation>
</ref>
<ref id="bibr8-0091270010396373">
<label>8.</label>
<citation citation-type="gov">
<collab>FDA guidance for industry population pharmacokinetics</collab>; <month>February</month>, <year>1999</year>. <comment><ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072137.pdf">http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072137.pdf</ext-link></comment>. <access-date>Accessed September 18, 2009</access-date>.</citation>
</ref>
<ref id="bibr9-0091270010396373">
<label>9.</label>
<citation citation-type="book">
<person-group person-group-type="editor">
<name><surname>Beal</surname><given-names>SL</given-names></name>
<name><surname>Sheiner</surname><given-names>LB</given-names></name>
</person-group>, eds. <source>NONMEM Users Guides</source>. <publisher-loc>Hanover, MD</publisher-loc>: <publisher-name>Globomax, LLC</publisher-name>; <year>1992</year>.</citation>
</ref>
<ref id="bibr10-0091270010396373">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sheiner</surname><given-names>LB</given-names></name>
</person-group>. <article-title>Learning versus confirming in clinical drug development</article-title>. <source>Clin Pharmacol Ther</source>. <year>1997</year>;<volume>61</volume>:<fpage>275</fpage>-<lpage>291</lpage>.</citation>
</ref>
<ref id="bibr11-0091270010396373">
<label>11.</label>
<citation citation-type="gov">
<collab>FDA guidance for industry pharmacokinetics in patients with impaired renal function—study design, data analysis, and impact on dosing and labeling</collab>; <day>14</day>, <month>May</month>, <year>1998</year>. <comment><ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072127.pdf">http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072127.pdf</ext-link></comment>. <access-date>Accessed 18, September, 2009</access-date></citation>
</ref>
</ref-list>
</back>
</article>